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Background. While 2% of all extranodal Non-Hodgkin Lymphomas present in the thyroid, there exists insufficient data to describe
the incidence of mantle cell lymphoma in the thyroid. A case series of 1400 patients revealed that <1% of thyroid lymphomas may
be MCL; hence better understanding of the disease course is essential. Patient Findings. A 65-year-old female was referred for a
multinodular goiter. Multiple fine needle aspirations from the dominant right nodule were consistent with Hashimoto’s thyroiditis
and flow cytometry was negative. Due to progressing dysphagia, she underwent total thyroidectomy. Summary. Pathology revealed
MCLwithmantle zone growth pattern in the right thyroid. Flow cytometry showedmonoclonal B cells comprising 9% of total cells.
The Ki-67 index was 10%. She was diagnosed as having stage IIE MCL and offered conservative management by medical oncology,
given that she had no B symptoms. Conclusion. Though chemotherapy is the treatment of choice in MCL, a subset of patients with
low-grade disease may be observed. As in our patient, mantle zone growth pattern and a Ki-67 index < 10% suggest a favorable
prognosis. A diagnosis of primary MCL in the thyroid remains rare and staging modalities as well as treatment options continue
to evolve.
1. Introduction
Primary thyroid lymphomas (PTL) are an infrequently
encountered diagnosis. Studies have suggested that less than
5% of all thyroid malignancies may be PTL [1]. Mantle cell
lymphoma (MCL) is one such type: it is an aggressive variant
of the Non-Hodgkin Lymphomas (NHL), accounting for less
than 10% of all NHL [2]. While most MCL present in lymph
nodes and may have extranodal involvement, less than a
quarter of all cases present primarily in extranodal sites [3].
These extranodal sites include gastrointestinal tract, liver,
spleen, peripheral blood, and central nervous system [2, 4].
A population-based study of PTL in about 1400 patients in
the United States revealed that only about 1% of patients had
MCL [5].
Mantle cell lymphomas primarily originate from the
pregerminal B cells of the mantle zone. They have been
consistently shown to have cyclin D1 overexpression, the
majority of which are caused by a bcl rearrangement t(11;14)
[6, 7]. This overexpression leads to unregulated cellular pro-
liferation and growth. Treatmentwith immunochemotherapy
is offered for most patients, while radiation therapy and stem
cell transplantation are used in selected patients [8].
Although oncologists describe MCL as more aggressive
than most NHL, the course of our patient was actually quite
favorable. This, accompanied by the lack of detailed clinical
descriptions of MCL presenting primarily in the thyroid
in the existing literature, makes this case valuable for both
educational and future research purposes.
2. Case Presentation
A 58-year-old female, with a past medical history of
Hashimoto’s thyroiditis, was referred to the Endocrinology
Clinic for evaluation of a multinodular goiter.This goiter was
initially discovered in 2000. She had previously undergone
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Figure 1: Right-sided dominant thyroid nodule seen on thyroid
ultrasonography.
fine needle aspiration (FNA) of a dominant thyroid nodule
(2.4 cm) on the right lobe.Thepathology for this had returned
benign, consistent with Hashimoto’s thyroiditis, and had a
negative flow cytometry. From 2000 to 2008, multiple FNAs
from the same nodule were consistent with the same result.
On presentation to our clinic in 2008, she was essentially
asymptomatic. She was clinically euthyroid. She did not have
any dyspnea, dysphagia, or dysphonia. On exam, she had
right-sided fullness of her thyroid and had an overall nodular
gland.Medical history other thanHashimoto’s thyroiditis and
the multinodular goiter included Type 2 diabetes mellitus,
osteopenia, hypertension, and hyperlipidemia. She was a
former smoker and had quit at the age of 34. Of note,
her mother had thyroid cancer, but the details of this
were not available. Her medications at that time included
levothyroxine, metformin, atorvastatin, lisinopril, and vita-
min D. Lab work revealed thyroid stimulating hormone
was 1.50 uUI/mL (0.28–3.89) with a free thyroxine level of
0.98 ng/dl (0.58–1.64). Her right nodule remained stable until
November 2014, when it was noted to have grown to 3.8 cm
(Figure 1). At that time, she complained of dysphagia and
neck discomfort. Given these symptoms, she underwent total
thyroidectomy in February 2015.
On gross examination, a large cystic nodule (4.2 cm)
was identified in the right lobe of the thyroid with multiple
smaller nodules in the left lobe. Sections from the right
thyroid nodule revealed dense lymphocytic infiltrate, which
formed variably sized follicles with germinal centers and
marked expansion of mantle zones surrounding the germinal
centers. The neoplastic cells in the mantle cell zones were
small with irregular nuclear contours, condensed chromatin,
and scant cytoplasm. A Delphian lymph node excision done
at the same time revealed similar involvement by mantle cell
lymphoma (Figures 2 and 3).
Immunoperoxidase stains revealed that the expanded
mantle zone cells (neoplastic B cells) were positive for CD20
(Figure 4), CD5 (Figure 5), CD43 (Figure 6), cyclin D1
(Figure 7), and SOX11 (Figure 8). Cyclin D1 and SOX11
Figure 2: Mantle cell lymphoma involving the thyroid and prela-
ryngeal lymph node (insert), stained with Hematoxylin and Eosin
(100x).
Figure 3: Mantle cell lymphoma involving the thyroid and prela-
ryngeal lymph node (insert), stained with Hematoxylin and Eosin
(400x).
also highlighted scattered interfollicular neoplastic B cells.
Concurrent flow cytometric analysis identified CD19+, CD20
bright+, CD5+, and CD10− monoclonal B cells with lambda
light chain restriction. These findings were consistent with
mantle cell lymphoma involving thyroid with predominantly
mantle zone growth pattern. FISH (fluorescence in situ
hybridization) analysis done on sections of the lymph node
showed a CCND1-IGH rearrangement, which occurs due to
chromosomal translocation t(11;14).The Ki-67 index was 10%
(Figure 9). Sections of the left lobe were negative for cyclin D1
and SOX11 stains.
She was referred to medical oncology and underwent
a bone marrow aspiration for staging. Her calculated MIPI
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Figure 4: Mantle cell lymphoma (100x). Positive staining with
CD20.
Figure 5: Mantle cell lymphoma (100x). Positive staining with CD5.
Figure 6: Mantle cell lymphoma involving thyroid (100x). Positive
staining with CD43.
Figure 7:Mantle cell lymphoma (100x). Positive stainingwith cyclin
D1.
Figure 8: Mantle cell lymphoma (100x). Positive staining with SOX
11.
Figure 9: Mantle cell lymphoma (100x). Ki67 staining.
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(MCL International Prognostic Index) was 3 and her Inter-
national Prognostic Index (IPI) was 1. This made her disease
of low risk.
She was diagnosed as having stage IIE MCL as she only
had disease in the thyroid and prelaryngeal lymph node
and the bone marrow biopsy was negative. Therapy was
not recommended because the patient was asymptomatic.
Under close surveillance, there has beenno evidence of tumor
recurrence or progression.
3. Discussion
PTL account for a small number of all thyroid malignancies,
between 2 and 5% of all cases [1, 11]. These are usually
Non-Hodgkin Lymphomas, andHodgkin’s Lymphoma in the
thyroid is exceedingly rare. PTL have been shown to have
preponderance in the elderly female population, presenting
mostly after the 5th decade of life [12]. It usually presents
as a rapidly enlarging painless mass, often with compressive
symptoms such as stridor, shortness of breath, and dysphagia
[11, 12]. Hashimoto’s thyroiditis is often implicated as a
risk factor for the development of PTL, where studies have
suggested that the risk is increased almost 60-fold compared
to the general population [13].
While the most common form of PTL is a diffuse large
B cell lymphoma, MCL is a rare variant. MCLs are usually
diagnosed at an advanced stage, with mostly extranodal
involvement [2]. The diagnosis is established by cytology
and distinguished via immunophenotyping. The detection
of t(11;14) by either karyotyping or FISH is very useful in
making this diagnosis. Another Non-Hodgkin Lymphoma
that is often difficult to differentiate fromMCL is themarginal
zone lymphoma (MZL).TheMZL is differentiated into nodal,
extranodal, and splenic types [14]. The MZL derives its
name from the origin of the lymphoma in the marginal
compartment of lymphoid tissues, while, similar to MCL,
these are positive for B cell markers CD-20 and CD-22; in
contrast the MZLs are negative to CD5. Additionally, the
MZLs do not carry the hallmark chromosomal translocation
of t(11;14) that is seen in MCL [7, 15].
MCLs are classified as an aggressive lymphoma, with
median survival of 3–5 years [16]. Prognosis is difficult to
quantify and several prognostic indices exist. One of the
previously used prognostic indices is the International Prog-
nostic Index (IPI) [17].This index accounts for age of patient,
stage of disease, serum lactate dehydrogenase, performance
status, and presence of extranodal sites. More recently, the
MIPI is being used to help risk-stratify patients with MCL at
diagnosis. This index utilizes age, performance status, lactate
dehydrogenase, and white cell count [18].
Treatment options for MCL have been evolving. They
have traditionally been based on chemotherapy with CHOP
regimens (cyclophosphamide, vincristine, doxorubicin, and
prednisone). More recently patients have been also treated
with immunotherapy (rituximab) and autologous stem cell
transplantation. Other agents being used are bendamustine
and lenalidomide plus rituximab [19]. Relapsed MCL is
considered to be even more challenging to treat and other
options are available under clinical trials, including ibrutinib,
bortezomib, and lenalidomide. Radiotherapy has also been
effectively used in the treatment of localized or refractory
MCL [20]. However, not all patients require treatment up
front as up to a third of MCL patients may be selected
for deferred treatment based on low IPI indices [21]. While
the MIPI can be variable, when combined with the Ki-
67 index, it can provide a more reliable tool for risk
assessment, which is called the MIPI-c index. The Ki67
antigen is a marker of cellular proliferation and therefore
useful in prognostications. One study revealed that the best
survival rate was with Ki-67 index of less than 10% [16].
Apart from the MIPI index and the Ki-67 index, a third
marker of indolent disease is the absence of SOX11. This is
a nuclear transcription factor and, if present, is implicated
in tumorogenesis that is seen in aggressive MCL. However,
when absent, it may correlate with improved survival. MCL
that is SOX-11 negativemay bemostly nonnodal presentation.
The absence of SOX11 expression not only has been linked
to indolent disease, but also is with improved survival. Other
indicators of good prognosis mentioned in the literature are
mutated IGHV gene and lack of mutations in 17p/TP 53
[22].
The presence of MCL primarily located in the thyroid is
scarcely reported. It is unclear whether the above-mentioned
prognostic indices and treatment regimens apply to MCL
that presents as a PTL. One case report highlighted the
discovery of MCL in the thyroid after a primary presentation
in the gastrointestinal tract [9]. This patient had a low Ki-
67 index [10–15%] and had good survival with continued
surveillance. Another case report demonstrating the presen-
tation ofMCL as a PTL did not have any other sites of disease;
however it did have a high Ki-67 index [>30%]. The patient
required 8 courses of immunochemotherapy (rituximab-
cyclophosphamide, epirubicin, vincristine, and prednisone)
and achieved complete remission [10] (see Table 1).
The description and clinical course of our patient appear
to be those of an indolent MCL, but whether she will
require treatment in the future is a question that remains
unanswered. In the absence of extensive data on the clin-
ical outcomes of MCL presenting as a PTL, more cases
are needed to better understand the disease course and
treatment options, as well as overall prognosis. It is also
important to note that though chemotherapy is the treatment
of choice for MCL, a small subset of patients with low-grade
disease may be observed. As in our patient, mantle zone
growth pattern and a Ki-67 index < 10% suggest a favorable
prognosis. Of note, the two previously reported cases of
MCL in the thyroid also exhibited no aggressive disease. A
diagnosis of primary MCL in the thyroid remains rare and
staging modalities as well as treatment options continue to
evolve.
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Table 1: Comparing our patient to another 2 cases reported in literature.
Our patient Hojilla et al. [9](2016)
Guastafierro et al. [10]
(2010)
Age of patient at diagnosis 63 59 59
Presence of Hashimoto’s thyroiditis Present Presence ofhypothyroidism Present
Stage of disease Stage II EA ? Stage I EA
Location of distant metastases None Involvement of colon ?
Ki-67 index 10%(lymph node)
10–15%
(in the colon) >30%
Treatment Surveillance Surveillance
8 courses of R-CEOP
(rituximab-cyclophosphamide,
epirubicin, vincristine, and
prednisone), followed by rituximab
for 2 years
Survival until publication Progression-free for 2years
Progression-free for 2
years Relapse-free for 4 years
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